Ovarian Cancer News and Research RSS Feed - Ovarian Cancer News and Research Twitter

Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
Researchers identify six mRNA isoforms that could be used to diagnose early-stage ovarian cancer

Researchers identify six mRNA isoforms that could be used to diagnose early-stage ovarian cancer

Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer. [More]
Clinical genomic sequencing could impact treatment decisions in advanced prostate cancer patients

Clinical genomic sequencing could impact treatment decisions in advanced prostate cancer patients

An international collaboration of researchers are advancing precision medicine to men with advanced prostate cancer. [More]
Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

A molecule that helps control gene expression may play a role in controlling chemotherapy resistance among patients with the most common form of ovarian cancer. [More]
Abcodia raises £5.25 million funding to launch ovarian cancer screening test, ROCA

Abcodia raises £5.25 million funding to launch ovarian cancer screening test, ROCA

Abcodia today announced that it has raised £5.25 million funding from existing and new investors to bring the world’s most sensitive and specific ovarian cancer screening test, ROCA to market. [More]
Study evaluates VolitionRx's proprietary Nucleosomics platform in most prevalent cancers

Study evaluates VolitionRx's proprietary Nucleosomics platform in most prevalent cancers

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has accelerated its large independent prospective study evaluating its proprietary Nucleosomics platform at University Hospital Bonn in Germany. [More]
First new treatment authorised in a decade for advanced cervical cancer patients in the UK

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

The European Commission has licensed Avastin in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. Until now, the treatment has been available ahead of licence to eligible patients in England via individual requests to the Cancer Drugs Fund (CDF). [More]
Vermillion reports expanded medical policy coverage of OVA1 test

Vermillion reports expanded medical policy coverage of OVA1 test

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, today announced expanded medical policy coverage of its OVA1 test, following Blue Cross Blue Shield of Michigan's recent decision to include OVA1 in its medical policy guidelines. [More]
Men with prostate cancer benefit from BRCA-targeting drug

Men with prostate cancer benefit from BRCA-targeting drug

Men with prostate cancer benefit from treatment with the pioneering drug olaparib - the first cancer drug to target inherited mutations - according to the results of a major trial presented today (Tuesday). [More]
Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer. [More]
Medical University of Vienna study supports use of ANGLE's Parsortix system for ovarian cancer study

Medical University of Vienna study supports use of ANGLE's Parsortix system for ovarian cancer study

ANGLE plc, the specialist medtech company, is delighted to announce that the Medical University of Vienna, one of its key opinion leaders, has published highly encouraging results in support of the use of ANGLE's Parsortix system in the detection of ovarian cancer. [More]
New Dream Team dedicated to ovarian cancer research formed at AACR Annual Meeting 2015

New Dream Team dedicated to ovarian cancer research formed at AACR Annual Meeting 2015

Stand Up To Cancer, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance, and National Ovarian Cancer Coalition, along with the American Association for Cancer Research, Scientific Partner to SU2C, announced today the formation of a Dream Team devoted to ovarian cancer research at the AACR Annual Meeting 2015, held here April 18-22. [More]
Research explores new, personalized ovarian cancer treatments

Research explores new, personalized ovarian cancer treatments

Identifying molecular changes that occur in tissue after chemotherapy could be crucial in advancing treatments for ovarian cancer, according to research from Magee-Womens Research Institute and Foundation and the University of Pittsburgh Cancer Institute, partner with UPMC CancerCenter, presented today at the American Association for Cancer Research Annual Meeting 2015. [More]
Zinc deficiency can activate Hedgehog signaling pathway

Zinc deficiency can activate Hedgehog signaling pathway

Zinc deficiency - long associated with numerous diseases, e.g. autism, lung cancer, prostate cancer, and ovarian cancers - can lead to activation of the Hedgehog signaling pathway, a biomolecular pathway that plays essential roles in developing organisms and in diseases, according to new research at Rensselaer Polytechnic Institute. [More]

President Bill Clinton honored with inaugural Tina's Wish Global Women's Health Award

Tina's Wish, the only nonprofit organization dedicated exclusively to funding research for the early detection of ovarian cancer, honored President Bill Clinton with the inaugural Tina's Wish Global Women's Health Award at a reception at the Waldorf Astoria New York on April 14th. [More]
Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

Nearly anyone touched by ovarian cancer will tell you: it's devastating. It's bad enough that cancer in almost 80 percent of patients reaches advanced stages before diagnosis, and that most patients are expected to die within five years. But just as painfully, roughly one quarter of women diagnosed have no warning that they are resistant to platinum-based chemotherapy, the main line of defense, nor that they will likely have 18 months to live. [More]
UAB research findings may lead to better treatment for women with HER2+ breast cancer

UAB research findings may lead to better treatment for women with HER2+ breast cancer

There are five subtypes of breast cancer, and they are distinct diseases with vastly different biologies that drastically alter their progression and responses to treatment. Understanding those differences is the starting point to a more effective, personalized treatment of breast cancer, which strikes more than 230,000 women in the U.S. each year. [More]
Women with ovarian cancer need to be tested for BRCA genes

Women with ovarian cancer need to be tested for BRCA genes

The genes BRCA1 and BRCA2 play a significant role in hereditary breast and ovarian cancers. Recent media attention has focused on American actress Angelina Jolie's decision to have her ovaries and fallopian tubes surgically removed after genetic testing for such cancers. [More]

Vermillion, Kaiser Permanente partner to enhance diagnosis, treatment of ovarian cancer

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, today announced the initiation of a strategic partnership with Kaiser Permanente's Southern California Permanente Medical Group in order to enhance the diagnosis and treatment of ovarian cancer. [More]

VolitionRx adds three new laboratory automation systems to expedite sample analysis for its large ongoing clinical trials

Using its first installed robot, VolitionRx has recently completed the analysis of a first NuQ® assay on the complete set of 4,800 blood samples for its large retrospective, symptomatic population colorectal cancer study in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark. [More]

Bright Pink, David's Bridal team up to raise awareness on breast and ovarian cancer

It's time to pucker up for a cause! Beginning today, David's Bridal will donate $1 (up to $100,000) to Bright Pink for every kiss sent on Instagram and Twitter using the hashtag #WithAKiss! [More]
Advertisement
Advertisement